Christoph Westphal and the crew at Novartis-backed TScan aren't waiting to take their preclinical TCR pitch to Nasdaq
Just 3 months ago, TScan CEO David Southwell told Endpoints News’ Nicole DeFeudis that it was likely the oncology startup would go public at some point, but just how soon after the $100 million crossover round they were reporting at the time hadn’t been decided.
Turns out, they were able to file confidentially 53 days after the crossover reveal, hustling ahead to catch the biggest financing wave in biotech history, as just about every stripe of biotech looks appetizing to investors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.